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Background: Liver cancer is one of the most frequent cancers in the world. Targeted therapy of cancer with
specific inhibitors is developing and has shown promising antitumor efficacy. CCI-779 (temsirolimus), a specific
inhibitor of mTOR (mammalian target of rapamycin), can block the mTOR signaling pathway. Here, we
systematically examined the expression of mTOR and its downstream targets in liver cancer cells and normal liver
cells, then investigated inhibitory effects of CCI-779 on mTOR signaling pathway and its role in regulating liver
cancer cell growth.
Methods: The expression of mTOR and its downstream targets in Bel-7402 liver cancer cells and HL-7702 normal
liver cells were examined by western blot. The mTOR specific inhibitor (CCI-779) was used to treat Bel-7402 cells to
identify its effects on Bel-7402 cell growth and activity of mTOR signaling pathway in vitro. Cell viability tests were
performed after the treatment of CCI-779. Western blot was applied to assess the changes of mTOR pathway and
flow cytometry was used to analyze cell cycle of Bel-7402 cells after the treatment of CCI-779.
Results: mTOR, p70S6K, S6, and 4EBP1 were overexpressed in Bel-7402 cells compared with HL-7702 cells. Bel-7402
cells were sensitive to CCI-779. The survival rate of the cells treated with CCI-779 over 0.312 μM was significantly
different compared with that of control (P < 0.05). CCI-779 inhibited the phosphorylation of mTOR (Ser2448), p70S6K
(Thr389), S6 (Ser240/244), and 4EBP1 (Thr37/46) in different grades and the expressions of p70S6K, S6, and 4EBP1. As
a result, CCI-779 induced a dose-dependent decrease in cell proliferation, G1/S arrest and damage of cell shape.
Conclusions: Taken together, these data showed that CCI-779 can inhibit mTOR signaling and proliferation in Bel-
7402 liver cancer cells in vitro. It offers a therapeutic intervention through inhibition of mTOR as a potential strategy
for liver cancer.
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Liver cancer is the sixth most common cancer worldwide
and the third leading cause of cancer-related death; 55% of
cases are in China [1]. Rates of liver cancer in men are typ-
ically 2 to 4 times higher than in women [2]. One of the
current treatments for liver cancer is liver transplantation.
Surgical resection of liver cancer is associated with a high
rate of recurrence [3], due to occult metastases that might
exist in the remnant liver at the time of resection or as a re-
sult of the ‘field’ effect in the remnant liver [4]. Thus, new* Correspondence: lswzg@imu.edu.cn
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reproduction in any medium, provided the ortherapeutic strategies are needed due to the poor prognosis
of patients with liver cancer. Targeting cancers with specific
inhibitors is a developing strategy and has shown promising
antitumor efficacy.
Increasing knowledge of the signal transduction pathways
of growth factors has implicated them as novel targets for
cancer therapy. Mammalian target of rapamycin (mTOR) is
an evolutionarily conserved protein kinase that belongs to
the phosphatidylinositol kinase-related kinase (PIKK) family
and functions as a serine/threonine kinase. Mounting evi-
dence has indicated that mTOR and its downstream targets
S6K1 and 4EBP1 are linked to tumorigenesis. These pro-
teins are often overexpressed or mutated in various cancershis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CCI-779 inhibits proliferation of Bel-7402 liver cancer
cells in vitro. (A) The effects of CCI-779 and its solvent DMSO on
Bel-7402 cell proliferation were examined by trypan blue exclusion
assay. (B) CCI-779 treatment on Day 1 and cell number for each
condition every 24 h until Day 8. diamond (♦ ), control (DMSO only);
rectangle (■), 1 μM of CCI-779; triangle (▲ ), 5 μM CCI-779; fork (×),
10 μM CCI-779; star (✼), 20 μM CCI-779.
Figure 2 Inhibition curve of CCI-779 on Bel-7402 growth.
Bel-7402 cells were treated with CCI-779 (0.25-28 μM) for 48 h, and
the susceptibility to CCI-779 was determined by MTT assay.
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of mTOR signaling is a promising therapeutic anti-cancer
strategy.
Rapamycin, the naturally occurring inhibitor of mTOR,
and several recently developed rapamycin analogs
(RAD001, CCI-779, AP23576, AZD8055) [6,7] inhibit the
growth of cell lines that have been derived from many
tumor types in vitro and tumor models in vivo [8]. CCI-
779, a dihydroxymethyl propionic acid ester of rapamycin,
or temsirolimus, is an effective inhibitor of mTOR. Several
groups have studied its suppression of various cancers
[9-11], and others have initiated a phase II study of CCI-
779 in breast cancer [12] and glioblastoma multiforme [13].
The clinical function of RAD001 has been studied [14], but
the inhibitive effects and therapeutic value of CCI-779 in
liver cancer remains unclear.
In this study, we analyzed the differences in mTOR ex-
pression between liver cancer and normal liver cells and
treated Bel-7402 liver cancer cells with CCI-779 to show
mTOR signaling has an important role in liver cancer cell
growth regulation. Our data showed the inhibitive effects of
CCI-779 on mTOR signaling and liver cancer cell growth.
It offers a therapeutic intervention through inhibition of
mTOR as a potential strategy for liver cancer.
Results and Discussion
CCI-779 inhibits proliferation of Bel-7402 liver cancer cells
The effects of CCI-779 on cell proliferation of Bel-7402
liver cancer cells were examined by trypan blue exclusion
assay. Bel-7402 cells were sensitive to CCI-779, and the
survival rate of the cells treated with CCI-779 over
0.312 μM was significantly suppressed compared with that
of control. There was no significant difference between
cells that were treated with 1% DMSO and the control
(Figure 1A). As shown in the growth curve in Figure 1B,
1 μM CCI-779 suppressed Bel-7402 growth from 4 to
8 days after treatment.
To determine the inhibitory effects of CCI-779 on cell
growth and optimize its concentration for subsequent ex-
periments, we calculated the half maximal inhibitory con-
centration (IC50) of CCI-779 in liver cancer cells. Bel-7402
cells were treated with various concentrations of CCI-779
(0.25 μM~28 μM) for 48 h, and their susceptibility to CCI-
779 was determined by MTT assay. The IC50 of CCI-779
on Bel-7402 cells was 8.62 μM (Figure 2).
mTOR, p70S6K, S6, and 4EBP1 are overexpressed in
Bel-7402 cells
To examine the expression of mTOR and its downstream
targets in Bel-7402 cells, we performed western blot ana-
lysis. As shown in Figure 3, the expression of mTOR,
p70S6K, S6, and 4EBP1 was higher in Bel-7402 cells than
in HL-7702 cells. The phosphorylation of these signaling
proteins was also greater in Bel-7402 versus HL-7702 cells.CCI-779 inhibits activation of mTOR and its downstream
targets
To determine the mechanism of CCI-779 inhibition in
Bel-7402 cells, we examined the activities of proteins in the
mTOR signaling pathway by western blot. They were:
mTOR and phospho-mTOR (Ser2448), downstream tar-
get p70S6K and p-p70S6K(Thr389), S6 and phospho-S6
(Ser240/244), 4EBP1 and p-4EBP1(Thr37/46). As shown in
Figure 3 Expression of mTOR, p70S6K, S6, and 4EBP1 is higher
in Bel-7402 cells versus HL-7702 cells. Expression of mTOR,
p70S6K, S6, and 4EBP1 was examined by western blot. β-actin
served as gel control.
Figure 4 Activation of mTOR and its downstream molecules is
inhibited by CCI-779 in Bel-7402 cells. Expression of mTOR,
p70S6K, S6, and 4EBP1 and phosphorylation status of mTOR
(Ser2448), p70S6K (Thr389), S6 (Ser240/244), and 4EBP1(Ser37/46)
were examined by western blot 48 h after the addition of CCI-779.
β-actin served as gel control.
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p70S6K, S6 and 4EBP1, and slightly suppressed the expres-
sions of mTOR, p70S6K, 4EBP1 and S6 in Bel-7402 cells.
CCI-779 induced G1/S cell-cycle arrest in Bel-7402 cells
To examine the effects of CCI-779 on cell cycle, Bel-
7402 cells were incubated with 5 μM CCI-779 for 48 h
and analyzed by flow cytometry. An inhibition of cell-
cycle progression occurred as a result of CCI-779 treat-
ment, as demonstrated by a decreased proportion of
cells in S phase (Figure 5). These results indicate that
CCI-779 can induce G1/S cell cycle arrest in Bel-7402
liver cancer cells.
Morphological changes in Bel-7402 cells after
CCI-779 treatment
mTOR is a central regulator of cell growth. With re-
gard to lethality, we determined the effects of CCI-779
(0.1~20 μM) treatment for 24 and 48 h on Bel-7402
cells. At concentrations of CCI-779 ≥1 μM, cell density
decreased and dead cells were observed (Figure 6).
Conventional therapeutic approaches for tumors in-
clude surgery, radiation, and chemotherapy. There has
been much recent progress in the development of pre-
ventive and therapeutic strategies that target molecules
in signal transduction pathways of cell proliferation, mi-
gration, and invasion in tumors [15-17]. Many specific
inhibitors have been identified and are beginning to beFigure 5 CCI-779 induces G1/S cell cycle arrest in Bel-7402
cells. CCI-779 treatment for 48 h and cell cycle analysis by flow
cytometry. (Ctr), control without CCI-779; (1), treatment with 5 μM
CCI-779 for 48 h.
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proliferative effects against a variety of human tumor-
derived cell lines [4,9,11,16,18] and has a good safety
profile in clinical trails [12,13,19].
We examined the expression of mTOR in Bel-7402 liver
cancer cells and HL-7702 normal liver cells by western blot.
Consistent with previous data, mTOR levels were elevated
in liver cancer cells versus normal liver cells. Further,
4EBP1, p70S6K, and S6 were also overexpressed. Rictor,
which complexes with mTOR, is highly expressed in liver
cancer [20]. These data indicate that the components of the
mTOR pathway are upregulated in tumor cells.
Treatment of Bel-7402 cells with CCI-779 does not affect
the phosphorylation of mTOR, p70S6K, or S6 after short
(30 min) stimulations [4]. However, we observed that the
phosphorylation of mTOR, p70S6K, 4EBP1 and S6 were
inhibited after 48 h of treatment with CCI-779. Our data
show that CCI-779 affects the activity of mTOR signaling
pathway has a time-dependent manner in liver cancer cells.
Meanwhile, the expression of p70S6K, 4EBP1 and S6 wereFigure 6 CCI-779 induces changes in morphology of Bel-7402
cells. Bel-7402 cells were treated with indicated concentrations of
CCI-779, and microscopic images were taken at 24 h (A) and 48 h
(B). Scale bar represents 50 micron.inhibited after 48 h of treatment with CCI-779. Similar re-
sults also were found in our previous studies on esophageal
tumor cells [21] and other groups [22,23]. The activity of
S6 and 4EBP1 will decreased when mTOR was inhibited by
its inhibitors, and then resulting in reduced protein synthe-
sis, but the precise mechanism is unclear now. It is believed
that the reduced expression of mTOR, 4EBP1 and S6 will
inhibit cell proliferation.
Further, epigenetic mechanisms also govern the devel-
opment of liver cancer. Several groups have found that
histone deacetylase and microRNA mediate the patho-
genesis of liver cancer [24,25]. These data demonstrate
the importance of the mTOR signaling pathway in regu-
lating cancer cell proliferation. Targeting proteins in the
mTOR signal pathway might be a more effective ap-
proach in developing new drugs. For example, FKBP38
is a key regulator of mTOR. The binding of FKBP38 to
mTOR inhibits the mTOR pathway; but Rheb can sup-
press FKBP38 and hence releases the growth signals
[26]. These discoveries provide more targets in studying
the inhibitors of the mTOR pathway and novel targets
for cancer therapies.
mTOR has been proposed to regulate the basic process
as a central regulator of cell growth [27], and there is a rela-
tionship between disorganization of the mTOR pathway
and tumors [28,29]. In a previous study, we demonstrated
that another clinical analog of rapamycin, RAD001, inhibits
the growth of esophageal cancer cells in vitro [21]. Several
studies have reviewed mTOR signaling in liver cancer and
the occurrence of tumors, therapy, and the design of
antitumor drugs [30,31]. The combination of two or more
inhibitors has been proposed to enhance their effects on
tumor suppression. Yet, attempts to combine two inhibitors
[32] have not been efficacious. Recent years, transgenic
mouse models in the development and progression of liver
cancer was developed [33,34]. Undoubtedly, it will be a
powerful tool that can be used to study liver cancer. Al-
though rapamycin and its analogs are well established as
anticancer drugs, new inhibitors of mTOR signaling must
be identified and designed.
Conclusions
In conclusion, our results demonstrate the importance
of the mTOR signaling pathway in regulating liver can-
cer cell proliferation. CCI-779 has inhibitory effects on
Bel-7402 liver cancer cells by suppressing the activity of
mTOR and its downstream components. Thus, inhib-
ition of mTOR is a potential therapeutic strategy for
liver cancer.
Materials and methods
Cell lines and culture conditions
Bel-7402 human liver cancer cells were grown in 1640
medium, supplemented with 10% heat-inactivated fetal
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maintained in 1640 medium, supplemented with 20%
heat-inactivated fetal bovine serum. All cell lines were
cultured in 5% CO2 at 37°C.
Reagents
CCI-779 (temsirolimus), a derivative of rapamycin, was
synthesized by Selleck Chemicals LLC (Huston, USA)
and dissolved in DMSO (Sigma Chemical Corp., St.
Louis, MO). The concentration of DMSO in the final so-
lution did not exceed 1% (v/v).
Trypan blue exclusion assay of cell proliferation
The antiproliferative effects of CCI-779 on Bel-7402 cells
in culture were measured by trypan blue exclusion assay.
Bel-7402 cells were used to seed 24-well culture plates
at 1×104 per well 24 h before drug treatment. For sensi-
tivity experiments, subconfluent cells were treated with
various concentrations CCI-779 (0.078 μM, 0.016 μM,
0.312 μM, 0.625 μM, 1.25 μM, 2.5 μM, and 5.0 μM) and
1% DMSO (v/v) for 48 h; harvested with trypsin; and
stained with trypan blue. Cell number was counted using
a hematocytometer.
For growth curve experiments, subconfluent cells were
treated with various concentrations of CCI-779 (1 μM,
5 μM, 10 μM, and 20 μM) for 48 h, harvested with tryp-
sin on the indicated day after treatment, and stained
with trypan blue. Cell number was counted using a
hematocytometer.
MTT assay and IC50 calculation
Exponentially growing cells were used to seed 96-well
plates at 4×103 cells per well 48 h before drug treatment.
Then, cells were incubated with CCI-779 at various con-
centrations (0.25 μM, 0.5 μM, 1.0 μM, 2.0 μM, 4.0 μM,
8.0 μM, 16.0 μM, 18.0 μM, 24.0 μM, and 28.0 μM) for
48 h. The medium with CCI-779 was absorbed, and
fresh medium was added. 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT, 5 g/l; Sigma-
Aldrich, USA) was added to each well and incubated for
4 h at 37°C. The solution was absorbed, and formazan
product was dissolved by adding 100 μl DMSO to each
well and incubated it for 10 min at 37°C. MTT absorb-
ance was measured at 490/630 nm with a spectropho-
tometer set (Thermo, Multiskan SX 353, USA). IC50 was
calculated by Logit model, based on the data.
Cell cycle analysis by flow cytometry
Bel-7402 cells were plated in 6-well tissue culture plates at
3×105 cells per well and incubated for 48 h at 37°C. For cell
cycle analysis, subconfluent cells were treated with 5 μM
CCI-779 for 48 h and harvested. Cells were washed with
cold PBS and stained with 50 mg/L propidium iodide (PI,Sigma-Aldrich, USA). DNA content was analyzed by flow
cytometry (FACS Calibur, Becton-Dickinson Co., USA).
Cell shape assay
Bel-7402 cells were used to seed 6-well culture plates at
3×105 per well 24 h before drug treatment. Cells were
treated with various concentrations of CCI-779 (0.1, 1,
10, and 20 μM) for 24 and 48 h and imaged with a
digital camera that was mounted on a light microscope
(Olympus DP-70, Japan).
Western blot analysis
Bel-7402 cells were plated in 6-well plates at 3×105 per
well and incubated for 24 h in medium. On the follow-
ing day, cells were treated with various concentrations of
CCI-779 (1 μM, 5 μM and 10 μM) for 48 h and
dissolved in cell lysis buffer (Thermo, USA). The con-
centrations of protein lysates were measured by Bio-Rad
protein determination method (Bio-Rad, CA, USA).
Equal amounts (40 μg) of protein were electrophoresed
in SDS-polyacrylamide gels, transferred to Immun-Blot™
PVDF membranes (Bio-RAD, CA, USA), and incubated
with primary antibodies overnight at 4°C and peroxidase-
linked secondary antibodies at room temperature for 1 h.
Enhanced chemiluminescence (ECL) (GE Healthcare, UK)
was used to detect the signals. The primary antibodies
were against mTOR, phosphor-mTOR (Ser2448), phos-
phor-p70S6K (Thr389) (Abcam, UK); S6, phosphor-S6
(Ser240/244), phosphor-4EBP1 (Thr37/46) (Cell Signaling
Technology, Inc., MA, USA); p70S6K, 4EBP1 (Santa Cruz
Biotechnology, Inc., CA, USA), and β-actin (Sigma-Aldrich,
USA).
Statistical analysis
Descriptive statistics were generated for all quantitative
data and expressed as mean ± SD. Proliferation of cells
that were exposed to the drugs was compared with that
of the negative control. Statistical significance was de-
fined as *p < 0.05.
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